PRA Health Sciences Stock Forecast, Price & News

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, PRAH shares have increased by 13.7% and is now trading at $100.83.
View which stocks have been most impacted by COVID-19.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for PRA Health Sciences.

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for PRA Health Sciences.

PRA Health Sciences Inc (NASDAQ:PRAH) announced its earnings results on Thursday, August, 6th. The medical research company reported $0.69 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.64 by $0.05. The medical research company earned $729.89 million during the quarter, compared to analyst estimates of $716.12 million. PRA Health Sciences had a net margin of 6.86% and a return on equity of 25.01%. PRA Health Sciences's revenue for the quarter was down 4.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.22 earnings per share.
View PRA Health Sciences' earnings history.

PRA Health Sciences issued an update on its FY20 earnings guidance on Thursday, August, 6th. The company provided EPS guidance of $4.35 to $4.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.37. The company issued revenue guidance of $3.07 billion to $3.13 billion, compared to the consensus revenue estimate of $3.07 billion.

13 brokers have issued 1-year price objectives for PRA Health Sciences' shares. Their forecasts range from $89.00 to $120.00. On average, they anticipate PRA Health Sciences' stock price to reach $105.75 in the next twelve months. This suggests a possible upside of 4.9% from the stock's current price.
View analysts' price targets for PRA Health Sciences.

PRA Health Sciences saw a increase in short interest in August. As of August 31st, there was short interest totaling 936,500 shares, an increase of 10.6% from the August 15th total of 846,400 shares. Based on an average daily volume of 311,500 shares, the short-interest ratio is currently 3.0 days. Approximately 1.5% of the shares of the company are sold short.
View PRA Health Sciences' Short Interest.

Some companies that are related to PRA Health Sciences include Incyte (INCY), PPD (PPD), EXACT Sciences (EXAS), Charles River Laboratories Intl. (CRL), Icon (ICLR), Exelixis (EXEL), Syneos Health (SYNH), Medpace (MEDP), BTG (BTGGF), National Research (NRC), Precigen (PGEN), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL), Luna Innovations (LUNA) and Pieris Pharmaceuticals (PIRS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Applied Materials (AMAT), Adobe (ADBE), Abbott Laboratories (ABT), Walt Disney (DIS), Paypal (PYPL), Veeva Systems (VEEV), Pfizer (PFE) and AbbVie (ABBV).

(PRAH) raised $306 million in an IPO on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.69%), NN Investment Partners Holdings N.V. (2.32%), NN Investment Partners Holdings N.V. (2.30%), Pendal Group Ltd (1.61%), Bank of New York Mellon Corp (1.18%) and Bamco Inc. NY (1.02%). Company insiders that own PRA Health Sciences stock include Christopher L Gaenzle, Colin Shannon, Fund Holdings LP Kkr and Michael J Bonello.
View institutional ownership trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Bank of America Corp DE, Bamco Inc. NY, First Trust Advisors LP, FMR LLC, Nuveen Asset Management LLC, Smith Asset Management Group LP, and UBS Group AG. Company insiders that have sold PRA Health Sciences company stock in the last year include Christopher L Gaenzle, Colin Shannon, and Michael J Bonello.
View insider buying and selling activity for PRA Health Sciences.

PRAH stock was bought by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Thrivent Financial for Lutherans, Bank of Nova Scotia, Bank of New York Mellon Corp, NN Investment Partners Holdings N.V., Canada Pension Plan Investment Board, NN Investment Partners Holdings N.V., and Man Group plc.
View insider buying and selling activity for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $100.83.

PRA Health Sciences has a market capitalization of $6.45 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 17,500 workers across the globe.

The official website for PRA Health Sciences is www.prahs.com.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]